ClinicalTrials.gg
CompletedNCT03212638Updated Mar 26, 2019Results posted

A Study of Baricitinib in Healthy Participants

A Phase 1 interventional study of Baricitinib suspension and Baricitinib tablet in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-26.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Study summary

The purposes of this study are to determine:

  • If there are any differences in the amount of baricitinib in the blood/body when taken in two different forms.
  • How a high-fat, high-calorie meal affects the amount of baricitinib in the blood/body.
  • The safety and tolerability of baricitinib.

The study has two parts. Individuals will participate in only one part.

Participants will be admitted to the clinical research unit (CRU) and will be discharged from the CRU following the completion of 3 overnight stays.

Each part of this study will last from 8-10 days, not including screening. Follow-up will occur 7 to 14 days after the last dose of baricitinib.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy males or females, as determined by medical history and physical examination
  • Women not of
  • Have a (BMI) of 18.5 to 29.9 kilograms per meter squared (kg/m²) inclusive, at screening

Exclusion criteria

Exclusion Criteria:

  • Have received (s) within 3 months of screening, or intend to during the study
  • Have a current or recent history (less than [\<] 30 days prior to screening and/or \<45 days prior to Day -1 in Period 1) of a bacterial, fungal parasitic, viral (not including rhinopharyngitis), or mycobacterial infection
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Baricitinib T1 (Part A)

    4 mg (milligram) baricitinib suspension test formulation (TF) administered orally (PO) without water following a 10 hour fast. (Baricitinib T1)

    Drug: Baricitinib suspension

  • Experimental
    Baricitinib T2 (Part A)

    4 mg baricitinib suspension formulation (TF) administered PO prior to 240 mL water following a 10 hour fast (Baricitinib T2)

    Drug: Baricitinib suspension

  • Experimental
    Baricitinib R (Part A)

    4 mg baricitinib tablet administered PO, taken with 240 mL water following a 10 hour fast (baricitinib R)

    Drug: Baricitinib tablet

  • Experimental
    Baricitinib TF Fasted (Part B)

    4 mg baricitinib suspension test formulation (TF) administered after 10 hour fast. (TF fasting)

    Drug: Baricitinib suspension

  • Experimental
    Baricitinib TF Fed (Part B)

    4 mg baricitinib suspension TF administered after a high fat meal.(baricitinib TF Fed)

    Drug: Baricitinib suspension

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Baricitinib Following a Single Oral Dose

    PK: Cmax of baricitinib after a single oral dose

    Time frame: Predose, 0.25 hour (hr), 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 9 hr, 12 hr, 24 hr, 36 hr, 48 hr postdose

  2. PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of Baricitinib Following a Single Oral Dose

    PK: AUC(0-tlast) of Baricitinib, measured in hour times nanogram per milliliter (ng\*hr/mL)

    Time frame: Predose, 0.25 hour (hr), 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 9 hr, 12 hr, 24 hr, 36 hr, 48 hr postdose

  3. PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Baricitinib Following a Single Oral Dose

    PK: AUC(0-∞) of Baricitinib

    Time frame: Predose, 0.25 hour (hr), 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 9 hr, 12 hr, 24 hr, 36 hr, 48 hr postdose

07

Results

Posted Mar 26, 2019

Participant flow

Period 1
Participant flow — Period 1
MilestonePart A: Sequence ABCPart A: Sequence BCAPart A: Sequence CABPart B: Sequence DEPart B:Sequence ED
Started88800
Received at least 1 dose of study drug88800
Completed88800
Not completed00000
Period 2
Participant flow — Period 2
MilestonePart A: Sequence ABCPart A: Sequence BCAPart A: Sequence CABPart B: Sequence DEPart B:Sequence ED
Started88800
Received at least 1 dose of study drug88800
Completed88800
Not completed00000
Period 3
Participant flow — Period 3
MilestonePart A: Sequence ABCPart A: Sequence BCAPart A: Sequence CABPart B: Sequence DEPart B:Sequence ED
Started88800
Received at least 1 dose of study drug88800
Completed88800
Not completed00000
Period 4
Participant flow — Period 4
MilestonePart A: Sequence ABCPart A: Sequence BCAPart A: Sequence CABPart B: Sequence DEPart B:Sequence ED
Started00099
Received at least 1 dose of study drug00099
Completed00099
Not completed00000
Period 5
Participant flow — Period 5
MilestonePart A: Sequence ABCPart A: Sequence BCAPart A: Sequence CABPart B: Sequence DEPart B:Sequence ED
Started00099
Received at least 1 dose of study drug00099
Completed00099
Not completed00000

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Baricitinib Following a Single Oral Dose

PK: Cmax of baricitinib after a single oral dose

Time frame:
Predose, 0.25 hour (hr), 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 9 hr, 12 hr, 24 hr, 36 hr, 48 hr postdose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Baricitinib Following a Single Oral Dose
nanograms per milliliter (ng/mL)Part A: Baricitinib T1Part A: Baricitinib T2Part A: Baricitinib RPart B: Baricitinib TF FastedPart B: Baricitinib TF Fed
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Baricitinib Following a Single Oral Dose49.8 ± 2149.6 ± 2447.8 ± 2547.9 ± 2232.5 ± 22
Statistical analysis
  • Part A: Baricitinib T1 vs Part A: Baricitinib R · Ratio: 1.04 · 95% CI 0.946 to 1.15
  • Part A: Baricitinib T2 vs Part A: Baricitinib R · Ratio: 1.04 · 95% CI 0.944 to 1.14
  • Part B: Baricitinib TF Fasted vs Part B: Baricitinib TF Fed · Ratio: 0.675 · 95% CI 0.617 to 0.740
PrimaryPK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of Baricitinib Following a Single Oral Dose

PK: AUC(0-tlast) of Baricitinib, measured in hour times nanogram per milliliter (ng\*hr/mL)

Time frame:
Predose, 0.25 hour (hr), 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 9 hr, 12 hr, 24 hr, 36 hr, 48 hr postdose
Reported as:
Geometric least squares mean · ng*hr/mL
PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of Baricitinib Following a Single Oral Dose
ng*hr/mLPart A: Baricitinib T1Part A: Baricitinib T2Part A: Baricitinib RPart B: Baricitinib TF FastedPart B: Baricitinib TF Fed
PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of Baricitinib Following a Single Oral Dose314 ± 19315 ± 17216 ± 18281 ± 22273 ± 20
Statistical analysis
  • Part A: Baricitinib T1 vs Part A: Baricitinib R · Ratio: 0.996 · 95% CI 0.963 to 1.03
  • Part A: Baricitinib T2 vs Part A: Baricitinib R · Ratio: 0.998 · 95% CI 0.995 to 1.03
  • Part B: Baricitinib TF Fasted vs Part B: Baricitinib TF Fed · Ratio: 0.973 · 95% CI 0.936 to 1.01
PrimaryPK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Baricitinib Following a Single Oral Dose

PK: AUC(0-∞) of Baricitinib

Time frame:
Predose, 0.25 hour (hr), 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 9 hr, 12 hr, 24 hr, 36 hr, 48 hr postdose
Reported as:
Geometric mean · ng*hr/mL
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Baricitinib Following a Single Oral Dose
ng*hr/mLPart A: Baricitinib T1Part A: Baricitinib T2Part A: Baricitinib RPart B: Baricitinib TF FastedPart B: Baricitinib TF Fed
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Baricitinib Following a Single Oral Dose319 ± 19319 ± 17319 ± 17284 ± 22282 ± 21
Statistical analysis
  • Part A: Baricitinib T1 vs Part A: Baricitinib R · Ratio: 0.999 · 95% CI 0.996 to 1.03
  • Part A: Baricitinib T2 vs Part A: Baricitinib R · Ratio: 0.999 · 95% CI 0.966 to 1.03
  • Part B: Baricitinib TF Fasted vs Part B: Baricitinib TF Fed · Ratio: 0.978 · 95% CI 0.941 to 1.02

Adverse events

Collected over Baseline through end of study (Up to 120 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Baricitinib T10/24 (0%)0/24 (0%)2/24 (8.3%)
Part A: Baricitinib T20/24 (0%)0/24 (0%)1/24 (4.2%)
Part A: Baricitinib R0/24 (0%)0/24 (0%)4/24 (16.7%)
Part B: Baricitinib TF Fasted0/18 (0%)0/18 (0%)1/18 (5.6%)
Part B: Baricitinib TF Fed0/18 (0%)0/18 (0%)5/18 (27.8%)
Most frequent other events
Most frequent other events
EventPart A: Baricitinib T1Part A: Baricitinib T2Part A: Baricitinib RPart B: Baricitinib TF FastedPart B: Baricitinib TF Fed
Upper respiratory tract infectionInfections and infestations0/240/240/240/184/18
Catheter site painGeneral disorders2/240/240/240/181/18
Catheter site swellingGeneral disorders2/241/241/240/181/18
Musculoskeletal painMusculoskeletal and connective tissue disorders0/240/242/240/180/18
Catheter site bruiseGeneral disorders0/240/241/240/181/18
PainGeneral disorders0/240/240/240/181/18
PyrexiaGeneral disorders0/240/240/240/181/18
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/240/240/241/180/18

Baseline characteristics

All participants in Part A or Part B that received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Part A:All ParticipantsPart B: All ParticipantsTotal
Mean39.9 ± 8.541.1 ± 11.340.4 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Part A:All ParticipantsPart B: All ParticipantsTotal
Female101
Male231841
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A:All ParticipantsPart B: All ParticipantsTotal
Hispanic or Latino000
Not Hispanic or Latino241842
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A:All ParticipantsPart B: All ParticipantsTotal
American Indian or Alaska Native000
Asian241741
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race011
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Part A:All ParticipantsPart B: All ParticipantsTotal
Singapore241842
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per meter squared (kg/m^2))Part A:All ParticipantsPart B: All ParticipantsTotal
Mean24.14 ± 2.5525.36 ± 3.0324.5 ± 2.8
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Singapore, Singapore
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Jul 2017, 1 month.

Results were first posted in Mar 2019, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2017
First posted
Jul 11, 2017
StartActual
Jun 27, 2017
Primary completionActual
Jul 31, 2017
CompletionActual
Nov 1, 2017
Results first posted
Mar 26, 2019
Last update
Mar 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03212638
Responsible party
Sponsor
First posted
Jul 11, 2017
Start date
Jun 27, 2017
Primary completion
Jul 31, 2017
Completion
Nov 1, 2017
Results posted
Mar 26, 2019
Last update
Mar 26, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion